Processing...
Clinical Trials for Kidney Cancer
Search
Search
There are 137 active trials for advanced/metastatic kidney cancer.
Click on a trial to see more information.
137 trials meet filter criteria.
Sort by:
HealthScout AI summary: Eligible patients are adults with advanced or metastatic solid tumors—including urothelial, triple negative breast, non-small cell lung, esophageal, pancreatic, ovarian, cervical (squamous), head and neck squamous cell, and prostate cancers—who have exhausted standard therapies and have ECOG 0–1. All participants receive intravenous LY4101174, a novel antibody-drug conjugate targeting nectin-4 and delivering a topoisomerase I inhibitor (exatecan).
ClinicalTrials.gov ID: NCT06238479
HealthScout AI summary: This trial enrolls adults with unresectable, recurrent, or metastatic solid tumors (including dedicated cohorts for melanoma post anti-PD-1 therapy and platinum-resistant ovarian cancer) to receive DF6215—a novel, half-life extended monovalent IL-2 agonist designed to selectively activate CD8+ T cells and NK cells—either alone or in combination with pembrolizumab. Participants must have ECOG 0-1, adequate organ function, and meet strict cardiac and infection criteria.
ClinicalTrials.gov ID: NCT06108479
HealthScout AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors—including a wide range such as head and neck, lung, bladder, prostate, breast, colorectal, and others—who have progressed on or are intolerant to standard therapies. Patients receive MGC026, a B7-H3-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor (exatecan), with cohorts in both dose escalation and expansion phases.
ClinicalTrials.gov ID: NCT06242470
HealthScout AI summary: This trial enrolls adults with advanced/metastatic renal cell carcinoma, non-small cell lung cancer, melanoma, gastric cancer, or colorectal cancer who have received multiple prior lines of therapy, and treats them with HFB200603, a BTLA (B and T lymphocyte attenuator) antagonist monoclonal antibody, as monotherapy or in combination with the anti-PD-1 antibody tislelizumab. Patients must have measurable disease, ECOG 0-1, and a tumor site amenable to biopsy.
ClinicalTrials.gov ID: NCT05789069
HealthScout AI summary: Eligible patients are adults with metastatic solid tumors (ECOG 0-1, measurable disease, adequate organ function) who will receive MDX2001, a tetraspecific antibody that engages T cells via CD3/CD28 and targets TROP2 and c-MET on tumor cells. The trial excludes individuals with major cardiac disease, active brain metastases, uncontrolled infections, or unresolved toxicities.
ClinicalTrials.gov ID: NCT06239194
HealthScout AI summary: This trial enrolls adults with selected advanced solid tumors—including NSCLC, renal cell carcinoma, melanoma, platinum-resistant ovarian cancer, nasopharyngeal carcinoma, and triple negative breast cancer—who have progressed after specific prior therapies, to evaluate the safety and dosing of KFA115 (a novel immunomodulatory small molecule, presumed to enhance anti-tumor immunity) as monotherapy and in combination with pembrolizumab. Exclusion criteria include significant cardiac, autoimmune, and interstitial lung diseases, as well as history of severe hypersensitivity to study drugs.
ClinicalTrials.gov ID: NCT05544929
HealthScout AI summary: Eligible patients have advanced, unresectable, or metastatic solid tumors of multiple types that are refractory to standard therapy and have a tumor accessible for intratumoral injection or biopsy. This trial evaluates the investigational oncolytic immunotherapy VET3-TGI (a vaccinia-derived agent engineered to kill tumor cells and modulate the tumor microenvironment via CXCR3, IL-12, and TGF-β inhibition) given by intratumoral or intravenous administration, alone or with pembrolizumab.
ClinicalTrials.gov ID: NCT06444815
HealthScout AI summary: Enrolling adult patients with stage IV NSCLC who developed acquired resistance after exactly one prior line of pembrolizumab or nivolumab, this trial investigates N-803 (an IL-15 superagonist immunotherapy stimulating NK and CD8+ T cells) in combination with docetaxel and continued PD-1 blockade. Patients must have measurable disease, ECOG 0-2, and adequate organ function.
ClinicalTrials.gov ID: NCT03228667
HealthScout AI summary: This trial enrolls adults with advanced solid tumors, including patients with RAS-altered tumors, previously treated advanced/metastatic renal cell carcinoma, and KRAS G12C-mutant cancers, to evaluate KO-2806, a next-generation farnesyltransferase inhibitor, as monotherapy or in combination with cabozantinib or adagrasib. KO-2806 targets RAS and other farnesylated proteins to inhibit oncogenic signaling and overcome resistance mechanisms.
ClinicalTrials.gov ID: NCT06026410
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors—including specified types such as head and neck squamous cell carcinoma, melanoma, NSCLC, cervical, triple negative breast, urothelial, and renal cell carcinoma—who have progressed after standard therapy or lack standard options, to receive the investigational agent MK-4700 (mechanism of action undisclosed) as monotherapy or in combination with the PD-1 inhibitor pembrolizumab. Key exclusions include active CNS metastases, significant comorbidities, or recent organ transplants.
ClinicalTrials.gov ID: NCT06894771